Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management

Q: What intervention is evaluated in the study?

The study evaluates patient-controlled subcutaneous analgesia with hydromorphone for managing cancer pain.

Q: How are efficacy outcomes assessed?

Efficacy is assessed using analgesic and symptom-related endpoints, with comparisons reported across study conditions and time points.

Q: What safety information is included?

The document includes safety findings such as adverse events and tolerability-related results for the evaluated regimen.

Sep 28, 2026

Uploaded by Aditya

Study examining patient-controlled subcutaneous analgesia using hydromorphone for cancer pain management. The document reports analgesic outcomes under specified protocols and includes statistical comparisons across groups, highlighting both efficacy measures and clinical parameters such as pain intensity and symptom response. Adverse events and safety considerations are also presented, including results for selected toxicity and tolerability endpoints. Publication metadata and identifiers are provided alongside study results.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Study overview

Analgesic outcomes and endpoints

Safety and adverse effects

Results and statistical findings

TY􀀁E O􀀐􀀉􀀝􀀉􀀍􀀌􀀘 R􀀂􀀓􀀂􀀌􀀐􀀆􀀇 􀀁UBL SHED 17 D􀀂􀀆􀀂􀀈b􀀂􀀐 2025 DO 10.3389/􀀎p􀀌􀀉􀀍 .2025.1674672 􀀁􀀂􀀃􀀄􀀁􀀂 􀀆􀀇 􀀁􀀂􀀃􀀂 􀀅􀀆􀀇􀀈􀀉􀀊􀀃􀀋 􀀅􀀃􀀌􀀍􀀎􀀏􀀐􀀊 􀀑􀀍􀀉􀀒􀀂􀀐􀀓􀀉􀀃􀀔􀀋 􀀅􀀃􀀌􀀍􀀎􀀏􀀐􀀊􀀋 􀀑􀀍􀀉􀀃􀀂􀀊 􀀅􀀃􀀌􀀃􀀂􀀓 􀀈􀀁􀀉􀀃􀀁􀀊􀀁􀀂 􀀆􀀇 􀀁􀀂􀀃􀀂 􀀅􀀆􀀇􀀈􀀉􀀊􀀃􀀋 􀀅􀀃􀀌􀀍􀀎􀀏􀀐􀀊 􀀑􀀍􀀉􀀒􀀂􀀐􀀓􀀉􀀃􀀔􀀋 􀀅􀀃􀀌􀀍􀀎􀀏􀀐􀀊􀀋 􀀑􀀍􀀉􀀃􀀂􀀊 􀀅􀀃􀀌􀀃􀀂􀀓􀀕􀀏􀀇􀀌􀀈􀀈􀀌􀀊􀀐􀀂􀀖􀀌 􀀗􀀘􀀉􀀍􀀂􀀙􀀌􀀊􀀎􀀌􀀐􀀊􀀋 􀀅􀀇􀀌􀀇􀀉􀀊 􀀚􀀂􀀇􀀂􀀓􀀇􀀃􀀉 􀀑􀀍􀀉􀀒􀀂􀀐􀀓􀀉􀀃􀀔 􀀏􀀎 􀀕􀀂􀀊􀀉􀀆􀀌􀀘􀀅􀀆􀀉􀀂􀀍􀀆􀀂􀀓􀀋 􀀛􀀐􀀌􀀍 􀀜􀀋􀀌􀀈􀀈􀀁􀀍􀀎􀀌􀀏􀀂􀀁􀀏􀀋􀀁 􀀁􀀂􀀍􀀝􀀞􀀉􀀍􀀝 􀀉􀀌􀀏 48701871@􀀇􀀂b􀀈u.􀀂􀀊u.􀀆􀀍 􀀈􀀁􀀋􀀁􀀃􀀉􀀁􀀂 21 N􀀏􀀒􀀂􀀈b􀀂􀀐 2025 􀀈􀀁􀀉􀀃􀀍􀀁􀀂 09 N􀀏􀀒􀀂􀀈b􀀂􀀐 2025 􀀐􀀋􀀋􀀁􀀎􀀄􀀁􀀂 01 D􀀂􀀆􀀂􀀈b􀀂􀀐 2025 􀀎􀀑􀀆􀀒􀀃􀀍􀀓􀀁􀀂 17 D􀀂􀀆􀀂􀀈b􀀂􀀐 2025 􀀋􀀃􀀄􀀐􀀄􀀃􀀌􀀏 W􀀌􀀍􀀝 Z 􀀌􀀍􀀊 􀀉􀀌􀀏 􀀁 (2025) 􀀁􀀌􀀃􀀉􀀂􀀍􀀃-􀀆􀀏􀀍􀀃􀀐􀀏􀀘􀀘􀀂􀀊􀀓ub􀀆u􀀃􀀌􀀍􀀂􀀏u􀀓 􀀌􀀍􀀌􀀘􀀝􀀂􀀓􀀉􀀌 w􀀉􀀃􀀇 􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂􀀉􀀍 􀀆􀀌􀀍􀀆􀀂􀀐 p􀀌􀀉􀀍 􀀈􀀌􀀍􀀌􀀝􀀂􀀈􀀂􀀍􀀃 . F􀀐􀀏􀀍􀀃 . 􀀁􀀌􀀉􀀍 R􀀂􀀓 . 6:1674672 . 􀀊􀀏􀀉: 10.3389/􀀎p􀀌􀀉􀀍 .2025.1674672 􀀋􀀌􀀎􀀇􀀈􀀃􀀔􀀓􀀄 © 2025 W􀀌􀀍􀀝 􀀌􀀍􀀊 􀀉􀀌􀀏 . T􀀇􀀉􀀓 􀀉􀀓 􀀌􀀍 􀀏p􀀂􀀍 -􀀌􀀆􀀆􀀂􀀓􀀓 􀀌􀀐􀀃􀀉􀀆􀀘􀀂 􀀊􀀉􀀓􀀃􀀐􀀉bu􀀃􀀂􀀊 u􀀍􀀊􀀂􀀐 􀀃􀀇􀀂 􀀃􀀂􀀐􀀈􀀓 􀀏􀀎􀀃􀀇􀀂 C􀀐􀀂􀀌􀀃􀀉􀀒􀀂 C􀀏􀀈􀀈􀀏􀀍􀀓 􀀗􀀃􀀃􀀐􀀉bu􀀃􀀉􀀏􀀍 L􀀉􀀆􀀂􀀍􀀓􀀂(CC 􀀚Y) . T􀀇􀀂 u􀀓􀀂􀀋 􀀊􀀉􀀓􀀃􀀐􀀉bu􀀃􀀉􀀏􀀍 􀀏􀀐 􀀐􀀂p􀀐􀀏􀀊u􀀆􀀃􀀉􀀏􀀍􀀉􀀍 􀀏􀀃􀀇􀀂􀀐 􀀎􀀏􀀐u􀀈􀀓 􀀉􀀓 p􀀂􀀐􀀈􀀉􀀃􀀃􀀂􀀊􀀋 p􀀐􀀏􀀒􀀉􀀊􀀂􀀊 􀀃􀀇􀀂􀀏􀀐􀀉􀀝􀀉􀀍􀀌􀀘 􀀌u􀀃􀀇􀀏􀀐(􀀓) 􀀌􀀍􀀊 􀀃􀀇􀀂 􀀆􀀏p􀀔􀀐􀀉􀀝􀀇􀀃 􀀏w􀀍􀀂􀀐(􀀓)􀀌􀀐􀀂 􀀆􀀐􀀂􀀊􀀉􀀃􀀂􀀊 􀀌􀀍􀀊 􀀃􀀇􀀌􀀃 􀀃􀀇􀀂 􀀏􀀐􀀉􀀝􀀉􀀍􀀌􀀘 pub􀀘􀀉􀀆􀀌􀀃􀀉􀀏􀀍􀀉􀀍 􀀃􀀇􀀉􀀓 􀀙􀀏u􀀐􀀍􀀌􀀘 􀀉􀀓 􀀆􀀉􀀃􀀂􀀊􀀋 􀀉􀀍 􀀌􀀆􀀆􀀏􀀐􀀊􀀌􀀍􀀆􀀂 w􀀉􀀃􀀇􀀌􀀆􀀆􀀂p􀀃􀀂􀀊 􀀌􀀆􀀌􀀊􀀂􀀈􀀉􀀆 p􀀐􀀌􀀆􀀃􀀉􀀆􀀂 . N􀀏 u􀀓􀀂􀀋􀀊􀀉􀀓􀀃􀀐􀀉bu􀀃􀀉􀀏􀀍 􀀏􀀐 􀀐􀀂p􀀐􀀏􀀊u􀀆􀀃􀀉􀀏􀀍 􀀉􀀓 p􀀂􀀐􀀈􀀉􀀃􀀃􀀂􀀊 w􀀇􀀉􀀆􀀇 􀀊􀀏􀀂􀀓 􀀍􀀏􀀃 􀀆􀀏􀀈p􀀘􀀔 w􀀉􀀃􀀇 􀀃􀀇􀀂􀀓􀀂 􀀃􀀂􀀐􀀈􀀓 . 􀀁􀀂􀀃􀀄􀀅􀀆􀀃􀀇􀀈􀀉􀀆􀀃􀀊􀀉􀀋􀀋􀀅􀀌 􀀎􀀏􀀐􀀈􀀏􀀃􀀂􀀆􀀅􀀉􀀏􀀎􀀂􀀆􀀂􀀋􀀑􀀅􀀎􀀄􀀂 􀀒􀀄􀀃􀀓 􀀓􀀔􀀌􀀊􀀉􀀕􀀉􀀊􀀖􀀓􀀉􀀆􀀅􀀄􀀆 􀀈􀀂􀀆􀀈􀀅􀀊 􀀖􀀂􀀄􀀆 􀀕􀀂􀀆􀀂􀀑􀀅􀀕􀀅􀀆􀀃 􀀗􀀓􀀉􀀆􀀑􀀘􀀂􀀄 􀀙􀀂􀀆􀀑 􀀚 􀀂􀀆􀀌 􀀁􀀅􀀆􀀑􀀛􀀄􀀆􀀑 􀀜􀀄􀀂􀀉􀀝􀀞 1 D􀀂p􀀌􀀐􀀃􀀈􀀂􀀍􀀃 􀀏􀀎 􀀁􀀌􀀉􀀍 􀀕􀀂􀀊􀀉􀀆􀀉􀀍􀀂 􀀌􀀍􀀊 R􀀂􀀇􀀌b􀀉􀀘􀀉􀀃􀀌􀀃􀀉􀀏􀀍􀀋 T􀀇􀀂 F􀀏u􀀐􀀃􀀇 H􀀏􀀓p􀀉􀀃􀀌􀀘 􀀏􀀎 H􀀂b􀀂􀀉 􀀕􀀂􀀊􀀉􀀆􀀌􀀘 􀀑􀀍􀀉􀀒􀀂􀀐􀀓􀀉􀀃􀀔􀀋􀀅􀀇􀀉􀀙􀀉􀀌􀀖􀀇u􀀌􀀍􀀝􀀋 H􀀂b􀀂􀀉􀀋 C􀀇􀀉􀀍􀀌􀀋 2D􀀂p􀀌􀀐􀀃􀀈􀀂􀀍􀀃 􀀏􀀎 R􀀇􀀂u􀀈􀀌􀀃􀀏􀀘􀀏􀀝􀀔 􀀌􀀍􀀊 􀀛􀀈􀀈u􀀍􀀏􀀘􀀏􀀝􀀔􀀋 T􀀇􀀂 F􀀏u􀀐􀀃􀀇 H􀀏􀀓p􀀉􀀃􀀌􀀘 􀀏􀀎 H􀀂b􀀂􀀉 􀀕􀀂􀀊􀀉􀀆􀀌􀀘 􀀑􀀍􀀉􀀒􀀂􀀐􀀓􀀉􀀃􀀔􀀋 􀀅􀀇􀀉􀀙􀀉􀀌􀀖􀀇u􀀌􀀍􀀝􀀋 H􀀂b􀀂􀀉􀀋 C􀀇􀀉􀀍􀀌 􀀆􀀕􀀖􀀗􀀘􀀙􀀚􀀛􀀜􀀝􀀞 C􀀌􀀍􀀆􀀂􀀐 p􀀌􀀉􀀍 􀀉􀀓 􀀌 􀀓􀀉􀀝􀀍􀀉ﬁ􀀆􀀌􀀍􀀃 pub􀀘􀀉􀀆 􀀇􀀂􀀌􀀘􀀃􀀇 􀀆􀀏􀀍􀀆􀀂􀀐􀀍 w􀀏􀀐􀀘􀀊w􀀉􀀊􀀂􀀋􀀍􀀂􀀆􀀂􀀓􀀓􀀉􀀃􀀌􀀃􀀉􀀍􀀝 􀀂􀀎􀀎􀀂􀀆􀀃􀀉􀀒􀀂 􀀈􀀌􀀍􀀌􀀝􀀂􀀈􀀂􀀍􀀃 􀀓􀀃􀀐􀀌􀀃􀀂􀀝􀀉􀀂􀀓 . T􀀇􀀉􀀓 􀀓􀀃u􀀊􀀔 􀀌􀀉􀀈􀀂􀀊 􀀃􀀏 􀀂xp􀀘􀀏􀀐􀀂􀀃􀀇􀀂 􀀂􀀎􀀎􀀂􀀆􀀃􀀓 􀀏􀀎 p􀀌􀀃􀀉􀀂􀀍􀀃-􀀆􀀏􀀍􀀃􀀐􀀏􀀘􀀘􀀂􀀊 􀀓ub􀀆u􀀃􀀌􀀍􀀂􀀏u􀀓 􀀌􀀍􀀌􀀘􀀝􀀂􀀓􀀉􀀌 (􀀁C􀀅􀀗) w􀀉􀀃􀀇􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂 􀀇􀀔􀀊􀀐􀀏􀀆􀀇􀀘􀀏􀀐􀀉􀀊􀀂 􀀉􀀍􀀙􀀂􀀆􀀃􀀉􀀏􀀍 􀀏􀀍 􀀐􀀂􀀎􀀐􀀌􀀆􀀃􀀏􀀐􀀔 􀀆􀀌􀀍􀀆􀀂􀀐 p􀀌􀀉􀀍 . eth􀀚􀀝s􀀞 W􀀂 􀀆􀀏􀀍􀀊u􀀆􀀃􀀂􀀊 􀀌 􀀐􀀂􀀃􀀐􀀏􀀓p􀀂􀀆􀀃􀀉􀀒􀀂 􀀏b􀀓􀀂􀀐􀀒􀀌􀀃􀀉􀀏􀀍􀀌􀀘 􀀓􀀃u􀀊􀀔 􀀉􀀍􀀒􀀏􀀘􀀒􀀉􀀍􀀝 p􀀌􀀃􀀉􀀂􀀍􀀃􀀓 w􀀇􀀏 􀀐􀀂􀀆􀀂􀀉􀀒􀀂􀀊 􀀁C􀀅􀀗 w􀀉􀀃􀀇 􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂 􀀇􀀔􀀊􀀐􀀏􀀆􀀇􀀘􀀏􀀐􀀉􀀊􀀂 􀀉􀀍􀀙􀀂􀀆􀀃􀀉􀀏􀀍 􀀌􀀃 􀀏u􀀐􀀇􀀏􀀓p􀀉􀀃􀀌􀀘 􀀎􀀐􀀏􀀈 D􀀂􀀆􀀂􀀈b􀀂􀀐 2022 􀀃􀀏 􀀕􀀌􀀔 2023 . 􀀗􀀘􀀘 p􀀌􀀃􀀉􀀂􀀍􀀃􀀓 􀀉􀀍 􀀃􀀇􀀉􀀓 􀀓􀀃u􀀊􀀔 w􀀂􀀐􀀂􀀉􀀍􀀉􀀃􀀉􀀌􀀘􀀘􀀔 􀀇􀀏􀀓p􀀉􀀃􀀌􀀘􀀉􀀖􀀂􀀊 􀀃􀀏 u􀀍􀀊􀀂􀀐􀀝􀀏 􀀊􀀏􀀓􀀂 􀀃􀀉􀀃􀀐􀀌􀀃􀀉􀀏􀀍 􀀌􀀍􀀊 􀀓􀀌􀀎􀀂􀀃􀀔 􀀌􀀓􀀓􀀂􀀓􀀓􀀈􀀂􀀍􀀃 􀀎􀀏􀀐􀀓ub􀀆u􀀃􀀌􀀍􀀂􀀏u􀀓 􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂 􀀁C􀀅􀀗􀀋 􀀂􀀍􀀓u􀀐􀀉􀀍􀀝 􀀊􀀐u􀀝 􀀃􀀏􀀘􀀂􀀐􀀌􀀍􀀆􀀂 􀀌􀀍􀀊 􀀓􀀃􀀌b􀀘􀀂 pu􀀈p 􀀏p􀀂􀀐􀀌􀀃􀀉􀀏􀀍 . 􀀗􀀎􀀃􀀂􀀐 􀀌􀀆􀀇􀀉􀀂􀀒􀀉􀀍􀀝 􀀊􀀏􀀓􀀂 􀀓􀀃􀀌b􀀉􀀘􀀉􀀖􀀌􀀃􀀉􀀏􀀍􀀋 􀀈􀀏􀀓􀀃 p􀀌􀀃􀀉􀀂􀀍􀀃􀀓 􀀆􀀏􀀍􀀃􀀉􀀍u􀀂􀀊􀀌􀀍􀀌􀀘􀀝􀀂􀀓􀀉􀀆 􀀃􀀇􀀂􀀐􀀌p􀀔 􀀌􀀃 􀀇􀀏􀀈􀀂 u􀀓􀀉􀀍􀀝 􀀃􀀇􀀂 pu􀀈p􀀋 w􀀉􀀃􀀇 􀀊􀀔􀀍􀀌􀀈􀀉􀀆 􀀈􀀏􀀍􀀉􀀃􀀏􀀐􀀉􀀍􀀝 􀀌􀀍􀀊􀀊􀀏􀀓􀀂 􀀌􀀊􀀙u􀀓􀀃􀀈􀀂􀀍􀀃􀀓 􀀆􀀏􀀍􀀊u􀀆􀀃􀀂􀀊 􀀒􀀉􀀌 􀀃􀀂􀀘􀀂p􀀇􀀏􀀍􀀂 􀀎􀀏􀀘􀀘􀀏w-up􀀓 􀀌􀀍􀀊 􀀏u􀀃p􀀌􀀃􀀉􀀂􀀍􀀃 􀀒􀀉􀀓􀀉􀀃􀀓 .􀀁􀀌􀀉􀀍 w􀀌􀀓 􀀌􀀓􀀓􀀂􀀓􀀓􀀂􀀊 u􀀓􀀉􀀍􀀝 􀀃􀀇􀀂 􀀍u􀀈􀀂􀀐􀀉􀀆􀀌􀀘 􀀐􀀌􀀃􀀉􀀍􀀝 􀀓􀀆􀀌􀀘􀀂 (NR􀀅)􀀋 w􀀇􀀉􀀘􀀂 􀀌􀀍x􀀉􀀂􀀃􀀔 􀀌􀀍􀀊􀀊􀀂p􀀐􀀂􀀓􀀓􀀉􀀏􀀍 w􀀂􀀐􀀂 􀀂􀀒􀀌􀀘u􀀌􀀃􀀂􀀊 u􀀓􀀉􀀍􀀝 􀀃􀀇􀀂 E􀀊􀀈􀀏􀀍􀀃􀀏􀀍 􀀅􀀔􀀈p􀀃􀀏􀀈 􀀗􀀓􀀓􀀂􀀓􀀓􀀈􀀂􀀍􀀃 􀀅􀀆􀀌􀀘􀀂(E􀀅􀀗􀀅-R) 􀀌􀀍􀀊 􀀓􀀘􀀂􀀂p 􀀞u􀀌􀀘􀀉􀀃􀀔 w􀀌􀀓 􀀈􀀂􀀌􀀓u􀀐􀀂􀀊 w􀀉􀀃􀀇 􀀃􀀇􀀂 􀀁􀀉􀀃􀀃􀀓bu􀀐􀀝􀀇 􀀅􀀘􀀂􀀂p Qu􀀌􀀘􀀉􀀃􀀔􀀛􀀍􀀊􀀂x (􀀁􀀅Q􀀛) . T􀀇􀀂 􀀉􀀍􀀆􀀉􀀊􀀂􀀍􀀆􀀂 􀀏􀀎 􀀌􀀊􀀒􀀂􀀐􀀓􀀂 􀀊􀀐u􀀝 􀀐􀀂􀀌􀀆􀀃􀀉􀀏􀀍􀀓 w􀀌􀀓 􀀌􀀘􀀓􀀏 􀀊􀀏􀀆u􀀈􀀂􀀍􀀃􀀂􀀊 . 􀀈es􀀛lts􀀞 T􀀇􀀂 􀀃􀀐􀀂􀀌􀀃􀀈􀀂􀀍􀀃 􀀊􀀂􀀈􀀏􀀍􀀓􀀃􀀐􀀌􀀃􀀂􀀊 􀀓􀀉􀀝􀀍􀀉ﬁ􀀆􀀌􀀍􀀃 􀀉􀀈p􀀐􀀏􀀒􀀂􀀈􀀂􀀍􀀃 􀀌􀀆􀀐􀀏􀀓􀀓 􀀌􀀘􀀘􀀏b􀀓􀀂􀀐􀀒􀀂􀀊 p􀀌􀀐􀀌􀀈􀀂􀀃􀀂􀀐􀀓 . 􀀗􀀎􀀃􀀂􀀐 􀀃􀀇􀀂 􀀆􀀏􀀍􀀃􀀉􀀍u􀀏u􀀓 􀀓ub􀀆u􀀃􀀌􀀍􀀂􀀏u􀀓 􀀉􀀍􀀙􀀂􀀆􀀃􀀉􀀏􀀍 􀀏􀀎􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂 􀀇􀀔􀀊􀀐􀀏􀀆􀀇􀀘􀀏􀀐􀀉􀀊􀀂 􀀉􀀍􀀎u􀀓􀀉􀀏􀀍 􀀎􀀏􀀐 􀀌􀀍􀀌􀀘􀀝􀀂􀀓􀀉􀀌􀀋􀀃􀀇􀀂 􀀈􀀂􀀊􀀉􀀌􀀍 NR􀀅 p􀀌􀀉􀀍􀀓􀀆􀀏􀀐􀀂 􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀊 􀀎􀀐􀀏􀀈 6 􀀃􀀏 1 ( 􀀁 < 0 . 0001)􀀋 􀀃􀀇􀀂 􀀈􀀂􀀌􀀍 􀀓􀀘􀀂􀀂p 􀀞u􀀌􀀘􀀉􀀃􀀔 􀀓􀀆􀀏􀀐􀀂􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀊 􀀎􀀐􀀏􀀈 13 . 85 􀀃􀀏 7 .488 ( 􀀁 < 0 . 0001)􀀋 􀀃􀀇􀀂 􀀈􀀂􀀊􀀉􀀌􀀍 􀀌􀀍x􀀉􀀂􀀃􀀔 􀀓􀀃􀀌􀀃􀀂 􀀓􀀆􀀏􀀐􀀂􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀊 􀀎􀀐􀀏􀀈 5 􀀃􀀏 1 ( 􀀁 < 0 . 0001)􀀋 􀀃􀀇􀀂 􀀈􀀂􀀊􀀉􀀌􀀍 􀀊􀀂p􀀐􀀂􀀓􀀓􀀉􀀏􀀍 􀀓􀀆􀀏􀀐􀀂 􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀊􀀎􀀐􀀏􀀈 􀀌 b􀀌􀀓􀀂􀀘􀀉􀀍􀀂 􀀏􀀎 3 􀀃􀀏 0 . 5 ( 􀀁 < 0 . 0001)􀀋 􀀌􀀍􀀊 􀀃􀀇􀀂 􀀈􀀂􀀊􀀉􀀌􀀍 􀀂􀀞u􀀉􀀒􀀌􀀘􀀂􀀍􀀃 􀀏􀀐􀀌􀀘􀀈􀀏􀀐p􀀇􀀉􀀍􀀂 􀀊􀀏􀀓􀀂 􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀊 􀀎􀀐􀀏􀀈 140 􀀈􀀝 􀀃􀀏 52 􀀈􀀝 ( 􀀁 < 0 . 0001) . 􀀋􀀚􀀜􀀖l􀀛si􀀚􀀜s􀀞 􀀁C􀀅􀀗 w􀀉􀀃􀀇 􀀇􀀔􀀊􀀐􀀏􀀈􀀏􀀐p􀀇􀀏􀀍􀀂 􀀇􀀔􀀊􀀐􀀏􀀆􀀇􀀘􀀏􀀐􀀉􀀊􀀂 􀀉􀀍􀀙􀀂􀀆􀀃􀀉􀀏􀀍 􀀏􀀎􀀎􀀂􀀐􀀓􀀓􀀉􀀝􀀍􀀉ﬁ􀀆􀀌􀀍􀀃 􀀃􀀇􀀂􀀐􀀌p􀀂u􀀃􀀉􀀆 b􀀂􀀍􀀂ﬁ􀀃􀀓 􀀎􀀏􀀐 􀀐􀀂􀀎􀀐􀀌􀀆􀀃􀀏􀀐􀀔 􀀆􀀌􀀍􀀆􀀂􀀐 p􀀌􀀉􀀍 . 􀀛􀀃 􀀂􀀎􀀎􀀂􀀆􀀃􀀉􀀒􀀂􀀘􀀔􀀐􀀂􀀊u􀀆􀀂􀀓 p􀀌􀀉􀀍 􀀉􀀍􀀃􀀂􀀍􀀓􀀉􀀃􀀔􀀋 􀀊􀀂􀀆􀀐􀀂􀀌􀀓􀀂􀀓 􀀏p􀀉􀀏􀀉􀀊 􀀊􀀏􀀓􀀌􀀝􀀂􀀋 􀀈􀀉􀀃􀀉􀀝􀀌􀀃􀀂􀀓 􀀆􀀂􀀐􀀃􀀌􀀉􀀍 􀀌􀀊􀀒􀀂􀀐􀀓􀀂􀀐􀀂􀀌􀀆􀀃􀀉􀀏􀀍􀀓􀀋 􀀌􀀍􀀊 􀀉􀀓 􀀌􀀓􀀓􀀏􀀆􀀉􀀌􀀃􀀂􀀊 w􀀉􀀃􀀇 􀀐􀀂􀀊u􀀆􀀂􀀊 􀀌􀀍x􀀉􀀂􀀃􀀔 􀀌􀀍􀀊 􀀊􀀂p􀀐􀀂􀀓􀀓􀀉􀀏􀀍 􀀌􀀓 w􀀂􀀘􀀘 􀀌􀀓􀀉􀀈p􀀐􀀏􀀒􀀂􀀊 􀀓􀀘􀀂􀀂p 􀀞u􀀌􀀘􀀉􀀃􀀔 . K􀀁􀀇􀀊􀀌􀀈􀀂􀀍 hy􀀝􀀙􀀚m􀀚􀀙ph􀀚􀀜e, s􀀛b􀀖􀀛t􀀕􀀜e􀀚􀀛s i􀀜je􀀖ti􀀚􀀜, 􀀙ef􀀙􀀕􀀖t􀀚􀀙y 􀀖􀀕􀀜􀀖e􀀙 p􀀕i􀀜, p􀀕i􀀜 s􀀖􀀚􀀙e, 􀀕􀀜xiety,􀀝ep􀀙essi􀀚􀀜 􀀆􀀃􀀊􀀉􀀌􀀏􀀈􀀃􀀄􀀉􀀆 􀀁􀀂􀀃 􀀅􀀆􀀇􀀈􀀉􀀇􀀊􀀋􀀊 􀀇􀀌 􀀍􀀎􀀉􀀏 􀀐􀀏􀀅􀀃􀀊 􀀇􀀌 􀀑􀀎􀀉􀀑􀀃􀀆 􀀋􀀊 􀀋􀀍􀀅􀀆􀀇􀀒􀀋􀀉􀀈 􀀃􀀎􀀑􀀂 􀀏􀀃􀀎􀀆􀀓 􀀍􀀃􀀎􀀉􀀋􀀉􀀈 􀀐􀀂􀀎􀀐 􀀐􀀂􀀃􀀅􀀆􀀃􀀒􀀎􀀔􀀃􀀉􀀑􀀃 􀀇􀀌 􀀅􀀎􀀐􀀋􀀃􀀉􀀐􀀊 􀀕􀀋􀀐􀀂 􀀑􀀎􀀉􀀑􀀃􀀆 􀀋􀀊 􀀋􀀉􀀑􀀆􀀃􀀎􀀊􀀋􀀉􀀈 􀀖􀀗􀀘􀀙􀀚􀀓 􀀔􀀃􀀎􀀛􀀋􀀉􀀈 􀀐􀀇 􀀎􀀉 􀀋􀀉􀀑􀀆􀀃􀀎􀀊􀀃 􀀋􀀉 􀀐􀀂􀀃􀀌􀀆􀀃􀀜􀀝􀀃􀀉􀀑􀀏 􀀇􀀌 􀀊􀀝􀀆􀀒􀀋􀀒􀀇􀀆􀀊􀀂􀀋􀀅 􀀋􀀊􀀊􀀝􀀃􀀊 􀀖􀀙 􀀓 􀀞􀀚 W􀀋􀀐􀀂 􀀐􀀂􀀃 􀀋􀀉􀀑􀀆􀀃􀀎􀀊􀀋􀀉􀀈 􀀉􀀝􀀍b􀀃􀀆 􀀇􀀌 􀀑􀀎􀀉􀀑􀀃􀀆 􀀑􀀎􀀊􀀃􀀊􀀓􀀑􀀎􀀉􀀑􀀃􀀆 􀀅􀀎􀀋􀀉 􀀂􀀎􀀊 b􀀃􀀑􀀇􀀍􀀃 􀀇􀀉􀀃 􀀇􀀌 􀀐􀀂􀀃 􀀍􀀇􀀊􀀐 􀀋􀀍􀀅􀀇􀀆􀀐􀀎􀀉

FAQs

What intervention is evaluated in the study?

The study evaluates patient-controlled subcutaneous analgesia with hydromorphone for managing cancer pain.

How are efficacy outcomes assessed?

Efficacy is assessed using analgesic and symptom-related endpoints, with comparisons reported across study conditions and time points.

What safety information is included?

The document includes safety findings such as adverse events and tolerability-related results for the evaluated regimen.

Sep 28, 2026

Uploaded by Aditya